NCT04475939: An ongoing trial by GlaxoSmithKline
This trial is ongoing. It must report results 1 month ago.
Full data
| Full entry on ClinicalTrials.gov | NCT04475939 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 26, 2020 |
| Completion date | Feb. 26, 2025 |
| Required reporting date | Feb. 26, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |